Literature DB >> 7300759

Paget's disease of bone: experiences with 100 patients treated with salmon calcitonin.

H S Grunstein, P Clifton-Bligh, S Posen.   

Abstract

ONe hundred patients with Paget's disease of bone were treated with salmon calcitonin. Seventy per cent of patients who presented with pain reported improvement of symptoms. Side effects which occurred in 53 patients were more severe in women, necessitating the withdrawal of therapy in 30% of women as against 7.5% of men. Five of the patients with intolerable side effects were subsequently able to tolerate porcine calcitonin, while six were unable to tolerate salmon, porcine or human calcitonin. No audiological improvement occurred. Aortic valve lesions were detected in 11 patients. After a mean treatment period of 7.8 months, serum alkaline phosphatase level was reduced by 39.3%. Total 24-hour urinary hydroxyproline was reduced by 46.1% after 11.2 months of treatment.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7300759     DOI: 10.5694/j.1326-5377.1981.tb128316.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  5 in total

Review 1.  Salmon calcitonin: a review of current and future therapeutic indications.

Authors:  C H Chesnut; M Azria; S Silverman; M Engelhardt; M Olson; L Mindeholm
Journal:  Osteoporos Int       Date:  2007-12-11       Impact factor: 4.507

2.  A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone.

Authors:  W D Fraser; T C Stamp; R A Creek; J P Sawyer; C Picot
Journal:  Postgrad Med J       Date:  1997-08       Impact factor: 2.401

3.  Low dose intravenous 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) for the treatment of Paget's disease of bone.

Authors:  J A Cantrill; H M Buckler; D C Anderson
Journal:  Ann Rheum Dis       Date:  1986-12       Impact factor: 19.103

4.  Paget's disease of bone. An update on management.

Authors:  D J Hosking
Journal:  Drugs       Date:  1985-08       Impact factor: 9.546

5.  Cardiovascular action of calcitonin gene-related peptide in humans.

Authors:  C Gennari; J A Fischer
Journal:  Calcif Tissue Int       Date:  1985-12       Impact factor: 4.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.